From 50 cells analyzed for each condition, the pictures in the right panel show representative images with the subcellular distribution of the autophagic vesicle marker LC3. *P < 0.001 comparing between HCC-827 cells and HCC-827IR cells. (D) Data analysis from GEO dataset of PARP1 mRNA ...
It could provide the trial with 50% power to detect an increase in median OS from a baseline of 12 months (chemotherapy) according to previous studies18 to 20 months (DCVAC/LuCa plus chemotherapy), with a two-sided significance level of α = 0.10. Sample size calculation was based on ...
(range, 0.4 to 62.0 months), KEYTRUDA plus chemotherapy in the neoadjuvant setting followed by KEYTRUDA as monotherapy after surgical resection significantly improved overall survival (OS), reducing the risk of death ...
For proliferation experiment, 2 Â 106 cells were injected subcutaneously in the right flank of 6-week-old BALB/c nude mice (n ¼ 12 per group). Mice were killed at 8 weeks, and primary tumours were isolated. For metastasis experiment, 1 Â 106 cells were injected into the lateral ...
We hypothesized that the 2-year survival with this radical therapy should be at least 20% with a one-sided 95% confidence interval (CI) not including 10% being the benchmark of 2-year survival with chemotherapy only.35 A sample size of 40 patients would be sufficient for this purpose. Re...
12 weeks (HR = 0.64; one sided P = 0.037) [139]. Based on these encouraging findings, phase III studies of vandetanib are currently underway. Axitinib (AG-013736) is a small molecule inhibitor that targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta, and cKIT. It was evaluated in a ...
(d) demonstrates wild type EGFR status.Bottom panel, findings of a 62-year-old woman with EGFR-mutant lung adenocarcinoma. CT (e) and PET (f) show a 2.6-cm-sized mass with mild18F–FDG uptake (pSUVmax = 4.8) in the right lower lobe. Hematoxylin-eosin staining (g) shows ...
Osimertinib is an effective treatment option for patients with advanced non-small cell lung cancer (NSCLC) with EGFR activation or T790M resistance mutations; however, acquired resistance to osimertinib can still develop. This study explored novel miRNA–mRNA regulatory mechanisms that contribute to ...
(Changsha, China). For tumorigenicity assays, 2 × 106stably transfected cells in 0.2 ml RPMI-1640 medium were injected subcutaneously into the right upper back of the mice. The tumor volume for each mouse was measured every 3 days. Three weeks after the injections, tumor-bearing ...
For the enrichment of biological terms and functional groups, we used the two-sided (enrichment/depletion) test based on the hyper-geometric distribution. We set the statistical significance to 0.05 (p≤ 0.05), and we used the Benjamini–Hochberg adjustment to correct the p-value for the terms...